Independent clinical studies

At GSK, we carry out a large number of studies on our products and we make this information available in a range of ways.

But we also recognise that there are investigators from other healthcare institutions or other forms of medical networks who have scientific questions and will seek our support to conduct this work. The majority of these requests relate to our products, but some research proposals might be disease-based or with another focus.  We refer to these as investigator-sponsored studies (ISS) and are open to applications for support.

Basis of support

We only support proposals that have a legitimate scientific purpose. The decision to support a study proposal is based on the importance of the research objectives to medical science and patient care, the scientific rationale for the proposed methodology, and the ability of the study sponsor to deliver a high-quality ethical study.

We do not support studies in order to reward healthcare professionals for using, purchasing, recommending, or prescribing GSK products or to persuade them to do so by supporting the proposed research. For more about our approach to working with healthcare professionals on research, read Collaborating on clinical trials and research.

We have an online system that enables researchers to create an account and submit study proposals. This site has been created to facilitate more timely reviews and decisions, and to allow users to follow the progress of their submission.

This portal automatically routes proposals to the appropriate GSK medical personnel based on the therapy area, GSK product, and country specified in the on-line proposal form.  Once received, all proposals are reviewed by GSK personnel to evaluate our ability and desire to support the proposed research.   

Go to the ISS study website to register and submit a proposal.


Collaborating on clinical trials and research

Working with healthcare professionals (HCPs) is an essential part or our efforts to develop new medicines and vaccines. These relationships help us understand both patient needs and the benefit and risks of our products.

Doctors and other Health Care Professionals (HCPs) help us by identifying potential volunteers for clinical trials, administer the investigational medicine or vaccine to the patients, and monitor the results. In this way their unique medical insight and knowledge is vital to the development of new treatments.

At the core of these relationships is a shared concern for improving the health of patients, based on our values of transparency, respect, integrity and patient focus. 

HCPs who work with us on clinical trials have contracts with us and are paid for their work on these clinical trials. This payment covers their time, plus the cost of investigations they may need to carry out regarding the suitability of a patient and the effectiveness of the treatment.


Our policies

We have strict policies governing all our work with HCPs. These state that:

  • all clinical trial investigators are selected solely on their qualifications to conduct good quality clinical research
  • their history of using, or not using, GSK products must not be taken into account when deciding whether to include them as clinical trial investigators
  • no payments are offered or made to influence their judgement on whether to enrol or maintain a patient in a clinical study
  • gifts are not permissible to healthcare professionals involved in research projects for GSK
  • all payments to HCPs must be governed by contracts
  • any payment must reflect fair market value for the work performed and the services provided.

We also have a commitment to publically disclose the research payments that are made to healthcare professionals and to their institutions for conducting clinical research.


Transparency disclosures (rest of world)

Outside of Europe and the USA, we continue to support and work towards transparency as industry associations or governments establish specific guidelines for disclosure.

We also continue to work towards publishing global figures at an aggregate level for the payments to HCPs that will continue, for activities such as advisory services and clinical research.